{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-002848","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.059002+00:00","generated_at":"2026-05-28T02:48:02.052563+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Standard BioTools reports preliminary FY2024 revenue ~$174M; Q4 ~$46.5M","bullets":["Preliminary Q4 2024 revenue approximately $46.5 million.","Full year 2024 revenue approximately $174 million, at top end of revised guidance.","CEO cites industry-wide headwinds and progress reducing operating expenses via SBS.","Company to discuss 2025 outlook when reporting final Q4/FY results later in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-002848","json":"https://secwatch.observer/filing/0001104659-25-002848.json","markdown":"https://secwatch.observer/filing/0001104659-25-002848.md","text":"https://secwatch.observer/filing/0001104659-25-002848.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000110465925002848/0001104659-25-002848-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000110465925002848/tm252898d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:48:02.052563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}